NewAmsterdam Pharma Company NV [NAMS] stock prices are up 1.64% to $22.93 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NAMS shares have gain 9.09% over the last week, with a monthly amount glided 27.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NewAmsterdam Pharma Company NV [NASDAQ: NAMS] stock has seen the most recent analyst activity on July 17, 2025, when Goldman initiated its Neutral rating and assigned the stock a price target of $27. Previously, Citigroup started tracking the stock with Buy rating on June 17, 2025, and set its price target to $42. On June 10, 2025, Stifel initiated with a Buy rating and assigned a price target of $44 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $42 on June 04, 2025. H.C. Wainwright initiated its recommendation with a Buy and recommended $48 as its price target on December 30, 2024. In a note dated March 14, 2024, Scotiabank initiated an Sector Outperform rating and provided a target price of $35 on this stock.
The stock price of NewAmsterdam Pharma Company NV [NAMS] has been fluctuating between $14.06 and $27.29 over the past year. Currently, Wall Street analysts expect the stock to reach $41 within the next 12 months. NewAmsterdam Pharma Company NV [NASDAQ: NAMS] shares were valued at $22.93 at the most recent close of the market. An investor can expect a potential return of 78.81% based on the average NAMS price forecast.
Analyzing the NAMS fundamentals
The NewAmsterdam Pharma Company NV [NASDAQ:NAMS] reported sales of 47.14M for trailing twelve months, representing a surge of 112.56%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -4.02%, Pretax Profit Margin comes in at -3.97%, and Net Profit Margin reading is -3.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.33 and Total Capital is -0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.29 points at the first support level, and at 21.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.27, and for the 2nd resistance point, it is at 23.62.
Ratios To Look Out For
It’s worth pointing out that NewAmsterdam Pharma Company NV [NASDAQ:NAMS]’s Current Ratio is 19.98. In addition, the Quick Ratio stands at 19.98 and the Cash Ratio stands at 18.29. Considering the valuation of this stock, the price to sales ratio is 54.61, the price to book ratio is 3.31.
Transactions by insiders
Recent insider trading involved Kling Douglas F, Chief Operating Officer, that happened on Jul 16 ’25 when 51043.0 shares were sold. Chief Operating Officer, Kling Douglas F completed a deal on Jul 15 ’25 to sell 47569.0 shares. Meanwhile, Affiliate NAP PoolCo B.V. bought 1.43 million shares on Jul 14 ’25.
